Peraso Inc 10-Q for FY2021 Q1
Peraso Inc. (PRSO)
About this 10-Q
Peraso Inc filed this 10-Q on May 13, 2021, covering the quarter ended March 31, 2021 (FY2021 Q1).
Headline figures
Quarter ended March 31, 2021, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Revenue
- $1.34M
- up 6.2% from $1.26M a year earlier
- Net loss
- $1.37M
- compared with a net loss of $1.41M a year earlier
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10-Q
(Mark one)
|
|
☒ |
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended March 31, 2021
OR
|
|
☐ |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission file number 000-32929
MOSYS, INC.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
77-0291941 |
|
(State or other jurisdiction |
|
(I.R.S. Employer |
|
of Incorporation or organization) |
|
Identification Number) |
2309 Bering Drive
San Jose, California, 95131
(Address of principal executive office and zip code)
(408) 418-7500
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading symbol(s)
|
Name of each exchange on which registered
|
|
Common Stock, par value $0.001 per share |
MOSY |
The Nasdaq Stock Market, LLC |
Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to filing requirements for the past 90 days. YES ☒ NO ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). YES ☒ NO ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:
|
Large accelerated filer |
☐ |
|
Accelerated filer |
☐ |
|
Non-accelerated filer |
☒ |
|
Smaller reporting company |
☒ |
|
Emerging growth company |
☐ |
|
|
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
The number of outstanding shares of the registrant’s common stock, par value $0.001 per share, was 6,134,719 as of May 7, 2021.
MOSYS, INC.
FORM 10-Q
March 31, 2021
|
PART I — |
3 |
|
|
|
|
|
|
Item 1. |
3 |
|
|
|
|
|
|
|
Condensed Consolidated Balance Sheets as of March 31, 2021 and December 31, 2020 |
3 |
|
|
|
|
|
|
4 |
|
|
|
|
|
|
|
5 |
|
|
|
|
|
|
|
Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2021 and 2020 |
6 |
|
|
|
|
|
|
7 |
|
|
|
|
|
|
Item 2. |
Management’s Discussion and Analysis of Financial Condition and Results of Operations |
16 |
|
|
|
|
|
Item 4. |
21 |
|
|
|
|
|
|
PART II — |
21 |
|
|
|
|
|
|
Item 1. |
21 |
|
|
|
|
|
|
Item 1A. |
21 |
|
|
|
|
|
|
Item 2. |
22 |
|
|
|
|
|
|
Item 6. |
23 |
|
|
|
|
|
|
|
24 |
MOSYS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except par value)
|
|
|
March 31, |
|
|
December 31, |
|
||
|
|
2021 |
|
|
2020 |
|
|||
|
|
|
(unaudited) |
|
|
|
|
|
|
|
ASSETS |
|
|
|
|
|
|
|
|
|
Current assets |
|
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
9,529 |
|
|
$ |
5,889 |
|
|
Short-term investments |
|
|
1,610 |
|
|
|
— |
|
|
Accounts receivable, net |
|
|
375 |
|
|
|
701 |
|
|
Inventories |
|
|
862 |
|
|
|
599 |
|
|
Prepaid expenses and other |
|
|
534 |
|
|
|
668 |
|
|
Total current assets |
|
|
12,910 |
|
|
|
7,857 |
|
|
Property and equipment, net |
|
|
105 |
|
|
|
121 |
|
|
Right-of-use lease asset, net |
|
|
254 |
|
|
|
303 |
|
|
Other |
|
|
18 |
|
|
|
17 |
|
|
Total assets |
|
$ |
13,287 |
|
|
$ |
8,298 |
|
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
|
|
|
|
|
|
Current liabilities |
|
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
81 |
|
|
$ |
76 |
|
|
Deferred revenue |
|
|
15 |
|
|
|
15 |
|
|
Short-term lease liability |
|
|
201 |
|
|
|
201 |
|
|
PPP note payable, current |
|
|
434 |
|
|
|
244 |
|
|
Accrued expenses and other |
|
|
1,291 |
|
|
|
1,300 |
|
|
Total current liabilities |
|
|
2,022 |
|
|
|
1,836 |
|
|
Convertible notes payable |
|
|
— |
|
|
|
3,092 |
|
|
PPP note payable |
|
|
145 |
|
|
|
335 |
|
|
Long-term lease liability |
|
|
57 |
|
|
|
103 |
|
|
Total liabilities |
|
|
2,224 |
|
|
|
5,366 |
|
|
Commitments and contingencies (Note 4) |
|
|
|
|
|
|
|
|
|
Stockholders’ equity |
|
|
|
|
|
|
|
|
|
Preferred stock, $0.01 par value; 20,000 shares authorized; none issued and outstanding |
|
|
— |
|
|
|
— |
|
|
Common stock, $0.001 par value; 120,000 shares authorized; 6,134 shares and 3,554 shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively |
|
|
6 |
|
|
|
3 |
|
|
Additional paid-in capital |
|
|
255,046 |
|
|
|
245,548 |
|
|
Accumulated other comprehensive loss |
|
|
(1 |
) |
|
|
— |
|
|
Accumulated deficit |
|
|
(243,988 |
) |
|
|
(242,619 |
) |
|
Total stockholders’ equity |
|
|
11,063 |
|
|
|
2,932 |
|
|
Total liabilities and stockholders’ equity |
|
$ |
13,287 |
|
|
$ |
8,298 |
|
The accompanying notes are an integral part of these condensed consolidated financial statements.
3
MOSYS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(Unaudited)
(In thousands, except per share data)
|
|
|
Three Months Ended |
|
|||||
|
|
|
March 31, |
|
|||||
|
|
|
2021 |
|
|
2020 |
|
||
|
Net revenue |
|
|
|
|
|
|
|
|
|
Product |
|
$ |
1,178 |
|
|
$ |
1,068 |
|
|
Royalty and other |
|
|
160 |
|
|
|
192 |
|
|
Total net revenue |
|
|
1,338 |
|
|
|
1,260 |
|
|
Cost of net revenue |
|
|
495 |
|
|
|
530 |
|
|
Gross profit |
|
|
843 |
|
|
|
730 |
|
|
Operating expenses |
|
|
|
|
|
|
|
|
|
Research and development |
|
|
1,159 |
|
|
|
961 |
|
|
Selling, general and administrative |
|
|
1,071 |
|
|
|
1,135 |
|
|
Total operating expenses |
|
|
2,230 |
|
|
|
2,096 |
|
|
Loss from operations |
|
|
(1,387 |
) |
|
|
(1,366 |
) |
|
Interest expense |
|
|
(30 |
) |
|
|
(55 |
) |
|
Other income, net |
|
|
48 |
|
|
|
16 |
|
|
Net loss |
|
$ |
(1,369 |
) |
|
$ |
(1,405 |
) |
|
|
|
|
|
|
|
|
|
|
|
Other comprehensive loss, net of tax: |
|
|
|
|
|
|
|
|
|
Net unrealized loss on available-for-sale securities |
|
|
(1 |
) |
|
|
— |
|
|
Comprehensive loss |
|
$ |
(1,370 |
) |
|
$ |
(1,405 |
) |
|
|
|
|
|
|
|
|
|
|
|
Net loss per share |
|
|
|
|
|
|
|
|
|
Basic and diluted |
|
$ |
(0.28 |
) |
|
$ |
(0.61 |
) |
|
|
|
|
|
|
|
|
|
|
|
Shares used in computing net loss per share |
|
|
|
|
|
|
|
|
|
Basic and diluted |
|
|
4,862 |
|
|
|
2,295 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of these condensed consolidated financial statements.
4
MOSYS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(Unaudited)
(In thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Additional |
|
|
Other |
|
|
|
|
|
|
|
|
|
||
|
|
|
Common Stock |
|
|
Paid-In |
|
|
Comprehensive |
|
|
Accumulated |
|
|
|
|
|
||||||||
|
|
|
Shares |
|
|
Amount |
|
|
Capital |
|
|
Loss |
|
|
Deficit |
|
|
Total |
|
||||||
|
Balance as of December 31, 2020 |
|
|
3,554 |
|
|
$ |
3 |
|
|
$ |
245,548 |
|
|
|
— |
|
|
$ |
(242,619 |
) |
|
$ |
2,932 |
|
|
Issuance of common stock under stock plan, net |
|
|
16 |
|
|
|
— |
|
|
|
(2 |
) |
|
|
— |
|
|
|
— |
|
|
|
(2 |
) |
|
Exercise of warrants |
|
|
1,033 |
|
|
|
1 |
|
|
|
2,477 |
|
|
|
— |
|
|
|
— |
|
|
|
2,478 |
|
|
Issuance of common stock for payment of accrued interest |
|
|
43 |
|
|
|
— |
|
|
|
140 |
|
|
|
— |
|
|
|
— |
|
|
|
140 |
|
|
Sale of common stock, net of placement costs |
|
|
1,488 |
|
|
|
2 |
|
|
|
6,815 |
|
|
|
— |
|
|
|
— |
|
|
|
6,817 |
|
|
Stock-based compensation |
|
|
— |
|
|
|
— |
|
|
|
68 |
|
|
|
— |
|
|
|
— |
|
|
|
68 |
|
|
Unrealized loss on available-for-sale investments |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(1 |
) |
|
|
— |
|
|
|
(1 |
) |
|
Net loss |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(1,369 |
) |
|
|
(1,369 |
) |
|
Balance as of March 31, 2021 |
|
|
6,134 |
|
|
$ |
6 |
|
|
$ |
255,046 |
|
|
$ |
(1 |
) |
|
$ |
(243,988 |
) |
|
$ |
11,063 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Additional |
|
|
Other |
|
|
|
|
|
|
|
|
|
||
|
|
|
Common Stock |
|
|
Paid-In |
|
|
Comprehensive |
|
|
Accumulated |
|
|
|
|
|
||||||||
|
|
|
Shares |
|
|
Amount |
|
|
Capital |
|
|
Loss |
|
|
Deficit |
|
|
Total |
|
||||||
|
Balance as of December 31, 2019 |
|
|
2,179 |
|
|
$ |
2 |
|
|
$ |
243,281 |
|
|
|
— |
|
|
$ |
(238,447 |
) |
|
$ |
4,836 |
|
|
Issuance of common stock for release of awards |
|
|
20 |
|
|
|
— |
|
|
|
(1 |
) |
|
|
— |
|
|
|
— |
|
|
|
(1 |
) |
|
Exercise of pre-funded warrants |
|
|
116 |
|
|
|
— |
|
|
|
2 |
|
|
|
— |
|
|
|
— |
|
|
|
2 |
|
|
Stock-based compensation |
|
|
— |
|
|
|
— |
|
|
|
68 |
|
|
|
— |
|
|
|
— |
|
|
|
68 |
|
|
Net loss |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(1,405 |
) |
|
|
(1,405 |
) |
|
Balance as of March 31, 2020 |
|
|
2,315 |
|
|
$ |
2 |
|
|
$ |
243,350 |
|
|
$ |
— |
|
|
$ |
(239,852 |
) |
|
$ |
3,500 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of these condensed consolidated financial statements.
5
MOSYS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(In thousands)
|
|
|
Three Months Ended |
|
|||||
|
|
|
March 31, |
|
|||||
|
|
|
2021 |
|
|
2020 |
|
||
|
Cash flows from operating activities: |
|
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(1,369 |
) |
|
$ |
(1,405 |
) |
|
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
18 |
|
|
|
41 |
|
|
Stock-based compensation |
|
|
68 |
|
|
|
68 |
|
|
Accrued interest |
|
|
30 |
|
|
|
55 |
|
|
Amortization of lease right-of-use asset |
|
|
49 |
|
|
|
47 |
|
|
Change in operating lease liability |
|
|
(46 |
) |
|
|
(50 |
) |
|
Gain on settlement of convertible notes payable and accrued interest, net |
|
|
(48 |
) |
|
|
— |
|
|
Changes in assets and liabilities: |
|
|
|
|
|
|
|
|
|
Accounts receivable |
|
|
325 |
|
|
|
636 |
|
|
Inventories |
|
|
(263 |
) |
|
|
(137 |
) |
|
Prepaid expenses and other assets |
|
|
134 |
|
|
|
(35 |
) |
|
Accounts payable |
|
|
5 |
|
|
|
(111 |
) |
|
Deferred revenue and other liabilities |
|
|
84 |
|
|
|
183 |
|
|
Net cash used in operating activities |
|
|
(1,013 |
) |
|
|
(708 |
) |
|
Cash flows from investing activities: |
|
|
|
|
|
|
|
|
|
Purchases of property and equipment |
|
|
(2 |
) |
|
|
(6 |
) |
|
Proceeds from maturities of short-term investments |
|
|
— |
|
|
|
300 |
|
|
Purchases of short-term investments |
|
|
(1,611 |
) |
|
|
— |
|
|
Net cash provided by (used in) investing activities |
|
|
(1,613 |
) |
|
|
294 |
|
|
Cash flows from financing activities: |
|
|
|
|
|
|
|
|
|
Proceeds from sale of common stock, net |
|
|
6,817 |
|
|
|
— |
|
|
Proceeds from exercise of common stock warrants |
|
|
2,478 |
|
|
|
2 |
|
|
Repayment of convertible notes payable |
|
|
(3,027 |
) |
|
|
— |
|
|
Taxes paid to net share settle equity awards |
|
|
(2 |
) |
|
|
(1 |
) |
|
Net cash provided by financing activities |
|
|
6,266 |
|
|
|
1 |
|
|
Net increase (decrease) in cash and cash equivalents |
|
|
3,640 |
|
|
|
(413 |
) |
|
Cash and cash equivalents at beginning of period |
|
|
5,889 |
|
|
|
6,053 |
|
|
Cash and cash equivalents at end of period |
|
$ |
9,529 |
|
|
$ |
5,640 |
|
|
Supplemental disclosure: |
|
|
|
|
|
|
|
|
|
Issuance of convertible notes in settlement of accrued interest |
|
$ |
— |
|
|
$ |
112 |
|
|
Settlement of accrued interest through issuance of common shares |
|
$ |
123 |
|
|
$ |
— |
|
The accompanying notes are an integral part of these condensed consolidated financial statements.
6
MOSYS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Note 1. The Company and Summary of Significant Accounting Policies
MoSys, Inc. (the Company) was incorporated in California in 1991 and reincorporated in 2000 in Delaware. The Company provides both integrated circuits (ICs) and intellectual property (IP) solutions that enable fast, intelligent data access and decision making for a wide range of markets. The Company’s primary product line is marketed under the Accelerator Engine name and includes the Bandwidth Engine IC products, which integrate the Company’s proprietary, 1T-SRAM high-density embedded memory and a highly-efficient serial interface protocol resulting in a monolithic memory IC solution optimized for memory bandwidth and transaction access performance. In 2020, the Company began offering for license the first of its Virtual Accelerator Engine products which consist of software, firmware and related IP. This new product line will include multiple function accelerator platform products, which target specific application functions and will use a common software interface to allow performance scalability over multiple hardware environments.
The accompanying condensed consolidated financial statements of the Company have been prepared without audit.
The condensed consolidated balance sheet as of December 31, 2020 has been derived from the audited consolidated financial statements at that date. Certain information and disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (GAAP) have been condensed or omitted in accordance with these rules and regulations of the Securities and Exchange Commission (SEC). The information in this report should be read in conjunction with the Company’s consolidated financial statements and notes thereto included in its most recent annual report on Form 10-K filed with the SEC.
In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company’s financial position, results of operations and cash flows for the interim periods presented. The operating results for the three months ended March 31, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021 or for any other future period.
Basis of Presentation
The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation. The Company’s fiscal year ends on December 31 of each calendar year.
Risks and Uncertainties
The Company is subject to risks from, among other things, competition associated with the industry in general, other risks associated with financing, liquidity requirements, rapidly changing customer requirements, limited operating history and the volatility of public markets.
COVID-19
The global outbreak of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency by the U.S. government in March 2020. This has negatively affected the U.S. and global economy, disrupted global supply chains, significantly restricted travel and transportation, resulted in mandated closures and orders to “shelter-in-place” and created significant disruption of the financial markets. The full extent of the COVID-19 impact on the Company’s operational and financial performance will depend on future developments, including the duration and spread of the pandemic and related actions taken by U.S. and foreign government agencies to prevent disease spread, all of which are uncertain, out of the Company’s control, and cannot be predicted.
Use of Estimates
The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at
7
the date of the financial statements and the reported amounts of revenues and expenses recognized during the reported period. Actual results could differ from those estimates.
Cash Equivalents and Investments
The Company has invested its excess cash in money market accounts, certificates of deposit, commercial paper, corporate debt, government-sponsored enterprise bonds and municipal bonds and considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents. Investments with original maturities greater than three months and remaining maturities less than one year are classified as short-term investments. Investments with remaining maturities greater than one year are classified as long-term investments. Management generally determines the appropriate classification of securities at the time of purchase. All securities are classified as available-for-sale. The Company’s available-for-sale short-term investments are carried at fair value, with the unrealized holding gains and losses reported in accumulated other comprehensive income. Realized gains and losses and declines in the value judged to be other than temporary are included in the other income, net line item in the condensed consolidated statements of operations and comprehensive loss. The cost of securities sold is based on the specific identification method.
Fair Value Measurements
The Company measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels:
Level 1— Inputs used to measure fair value are unadjusted quoted prices that are available in active markets for the identical assets or liabilities as of the reporting date.
Level 2— Pricing is provided by third party sources of market information obtained through the Company’s investment advisors, rather than models. The Company does not adjust for, or apply, any additional assumptions or estimates to the pricing information it receives from advisors. The Company’s Level 2 securities may include cash equivalents and available-for-sale securities, which consist primarily of certificates of deposit, corporate debt, and government agency and municipal debt securities from issuers with high-quality credit ratings. The Company’s investment advisors obtain pricing data from independent sources, such as Standard & Poor’s, Bloomberg and Interactive Data Corporation, and rely on comparable pricing of other securities because the Level 2 securities are not actively traded and have fewer observable transactions. The Company considers this the most reliable information available for the valuation of the securities.
Level 3— Unobservable inputs that are supported by little or no market activity and reflect the use of significant management judgment are used to measure fair value. These values are generally determined using pricing models for which the assumptions utilize management’s estimates of market participant assumptions. The determination of fair value for Level 3 investments and other financial instruments involves the most management judgment and subjectivity.
Allowance for Doubtful Accounts
The Company establishes an allowance for doubtful accounts to ensure that its trade receivables balances are not overstated due to uncollectibility. The Company performs ongoing customer credit evaluations within the context of the industry in which it operates and generally does not require collateral from its customers. A specific allowance of up to 100% of the invoice value is provided for any problematic customer balances. Delinquent account balances are written off after management has determined that the likelihood of collection is remote. The Company grants credit only to customers deemed creditworthy in the judgment of management. The allowance for doubtful accounts was $41,000 at March 31, 2021 and December 31, 2020.
Inventories
The Company values its inventories at the lower of cost, which approximates actual cost on a first-in, first-out basis, or net realizable value. The Company records inventory reserves for estimated obsolescence or unmarketable inventories based upon assumptions about future demand and market conditions. Once a reserve is established, it is maintained until the product to which it relates is sold or otherwise disposed of. If actual market conditions are less favorable than those expected by management, additional adjustment to inventory valuation may be required. Charges for obsolete and slow-moving inventories are recorded based upon an analysis of specific identification of obsolete inventory items and
8
quantification of slow moving inventory items. The Company recorded no material write-downs of inventory during the three months ended March 31, 2021 and recorded write-downs of $0.1 million for the year ended December 31, 2020.
Revenue Recognition
The Company generates revenue primarily from sales of IC products and licensing of its IP. Revenues are recognized when control is transferred to customers in amounts that reflect the consideration the Company expects to be entitled to receive in exchange for those goods. Revenue recognition is evaluated through the following five steps: (i) identification of the contract, or contracts, with a customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when or as a performance obligation is satisfied.
IC products
Revenue is recognized when performance obligations under the terms of a contract with a customer are satisfied.
The majority of the Company’s contracts have a single performance obligation to transfer products. Accordingly, the Company recognizes revenue when title and risk of loss have been transferred to the customer, generally at the time of shipment of products. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products and is generally based upon a negotiated, formula, list or fixed price. The Company sells its products both directly to customers and through distributors generally under agreements with payment terms typically less than 60 days.
Royalty and other
The Company’s licensing contracts typically provide for royalties based on the licensee’s use of the Company’s memory technology in its currently shipping commercial products. The Company estimates its royalty revenue in the calendar quarter in which the licensee uses the licensed technology. Payments are generally received in the subsequent quarter.
Contract liabilities – deferred revenue
The Company’s contract liabilities consist of advance customer payments and deferred revenue. The Company classifies advance customer payments and deferred revenue as current or non-current based on the timing of when the Company expects to recognize revenue.
During the three months ended March 31, 2021, the Company recognized no revenue that had been included in deferred revenue as of December 31, 2020.
See Note 5 for disaggregation of revenue by geography.
Cost of Net Revenue
Cost of net revenue consists primarily of direct and indirect costs of IC product sales and engineering personnel costs directly related to maintenance and support services specified in licensing agreements. Maintenance and support typically include engineering support to assist in the commencement of production of a licensee’s products.
Warrants
As of March 31, 2021, the Company had the following warrants outstanding (share amounts in thousands):
|
|
|
|
||||||||
|
Warrant Type |
|
Number of Shares |
|
|
Exercise Price |
|
|
Expiration |
||
|
Common stock |
|
|
33 |
|
|
$ |
47.00 |
|
|
January 2023 |
|
Common stock |
|
|
813 |
|
|
$ |
2.40 |
|
|
October 2023 |
9
Per Share Amounts
Basic net income (loss) per share is computed by dividing net income (loss) for the period by the weighted-average number of shares of common stock outstanding during the period. Diluted net income (loss) per share gives effect to all potentially dilutive shares of common stock outstanding during the period. Potentially dilutive shares of common stock consist of incremental shares of common stock issuable upon the exercise of stock options, vesting of stock awards and shares issuable in conjunction with convertible notes.
The following table sets forth securities outstanding that were excluded from the computation of diluted net loss per share as their inclusion would be anti-dilutive (in thousands):
|
|
|
March 31, |
|
|||||
|
|
|
2021 |
|
|
2020 |
|
||
|
Options outstanding to purchase common stock |
|
|
159 |
|
|
|
161 |
|
|
Unvested restricted common stock units |
|
|
58 |
|
|
|
82 |
|
|
Convertible notes |
|
|
- |
|
|
|
254 |
|
|
Warrants |
|
|
846 |
|
|
|
1,879 |
|
|
Total |
|
|
1,063 |
|
|
|
2,376 |
|
Note 2: Fair Value of Financial Instruments
The estimated fair values of financial instruments outstanding were (in thousands):
|
|
|
March 31, 2021 |
|
|||||||||||||
|
|
|
|
|
|
|
Unrealized |
|
|
Unrealized |
|
|
Fair |
|
|||
|
|
|
Cost |
|
|
Gains |
|
|
Losses |
|
|
Value |
|
||||
|
Cash and cash equivalents |
|
$ |
9,529 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
9,529 |
|
|
Short-term investments |
|
|
1,611 |
|
|
|
— |
|
|
|
(1 |
) |
|
|
1,610 |
|
|
|
|
$ |
11,140 |
|
|
$ |
— |
|
|
$ |
(1 |
) |
|
$ |
11,139 |
|
|
|
|
December 31, 2020 |
|
|||||||||||||
|
|
|
|
|
|
|
Unrealized |
|
|
Unrealized |
|
|
Fair |
|
|||
|
|
|
Cost |
|
|
Gains |
|
|
Losses |
|
|
Value |
|
||||
|
Cash and cash equivalents |
|
$ |
5,889 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
5,889 |
|
The following table represents the Company’s fair value hierarchy for its financial assets (cash equivalents and investments) (in thousands):
|
|
|
March 31, 2021 |
|
|||||||||||||
|
|
|
Fair Value |
|
|
Level 1 |
|
|
Level 2 |
|
|
Level 3 |
|
||||
|
Money market funds |
|
$ |
7,276 |
|
|
$ |
7,276 |
|
|
$ |
— |
|
|
$ |
— |
|
|
Corporate notes and commercial paper |
|
$ |
1,610 |
|
|
$ |
— |
|
|
$ |
1,610 |
|
|
$ |
— |
|
|
|
|
December 31, 2020 |
|
|||||||||||||
|
|
|
Fair Value |
|
|
Level 1 |
|
|
Level 2 |
|
|
Level 3 |
|
||||
|
Money market funds |
|
$ |
3,893 |
|
|
$ |
3,893 |
|
|
$ |
— |
|
|
$ |
— |
|
There were no transfers in or out of Level 1 and Level 2 securities during the three months ended March 31, 2021 or 2020.
10
Note 3. Balance Sheet Detail
|
|
|
March 31, |
|
|
December 31, |
|
||
|
|
|
2021 |
|
|
2020 |
|
||
|
|
|
(in thousands) |
|
|||||
|
Inventories: |
|
|
|
|
|
|
|
|
|
Work-in-process |
|
$ |
654 |
|
|
$ |
414 |
|
|
Finished goods |
|
|
208 |
|
|
|
185 |
|
|
|
|
$ |
862 |
|
|
$ |
599 |
|
Note 4. Commitments and Contingencies
Indemnification
In the ordinary course of business, the Company enters into contractual arrangements under which it may agree to indemnify the counterparties from any losses incurred relating to breach of representations and warranties, failure to perform certain covenants, or claims and losses arising from certain events as outlined within the particular contract, which may include, for example, losses arising from litigation or claims relating to past performance. Such indemnification clauses may not be subject to maximum loss clauses. The Company has also entered into indemnification agreements with its officers and directors. No material amounts were reflected in the Company’s condensed consolidated financial statements for the three months ended March 31, 2021 or 2020 related to these indemnifications.
The Company has not estimated the maximum potential amount of indemnification liability under these agreements due to the limited history of prior claims and the unique facts and circumstances applicable to each particular agreement. To date, the Company has not made any material payments related to these indemnification agreements.
Legal Matters
The Company is not a party to any legal proceeding that the Company believes is likely to have a material adverse effect on its condensed consolidated financial position or results of operations. From time to time the Company may be subject to legal proceedings and claims in the ordinary course of business. These claims, even if not meritorious, could result in the expenditure of significant financial resources and diversion of management efforts.
Note 5. Business Segments, Concentration of Credit Risk and Significant Customers
The Company operates in one business segment and uses one measurement of profitability for its business. Net revenue is attributed to the United States and to all foreign countries based on the geographical location of the customer.
The Company recognized revenue from shipment of product and licensing of its technologies to customers by geographical location as follows (in thousands):
|
|
|
Three Months Ended |
|
|||||
|
|
|
March 31, |
|
|||||
|
|
|
2021 |
|
|
2020 |
|
||
|
North America |
|
$ |
948 |
|
|
$ |
812 |
|
|
Japan |
|
|
274 |
|
|
|
237 |
|
|
Taiwan |
|
|
79 |
|
|
|
138 |
|
|
Rest of world |
|
|
37 |
|
|
|
73 |
|
|
Total net revenue |
|
$ |
1,338 |
|
|
$ |
1,260 |
|
11
Customers who accounted for at least 10% of total net revenue were:
|
|
|
Three Months Ended |
||
|
|
|
March 31, |
||
|
|
|
2021 |
|
2020 |
|
Customer A |
|
38% |
|
26% |
|
Customer B |
|
20% |
|
19% |
|
Customer C |
|
18% |
|
14% |
|
Customer D |
|
*% |
|
12% |
|
Customer E |
|
*% |
|
11% |
|
* |
Represents less than 10% |
Three customers accounted for 74% of accounts receivable as of March 31, 2021. Three customers accounted for 86% of accounts receivable as of December 31, 2020.
Note 6. Income Tax Provision
The Company determines deferred tax assets and liabilities based upon the differences between the financial statement and tax bases of the Company’s assets and liabilities using tax rates in effect for the year in which the Company expects the differences to affect taxable income. A valuation allowance is established for any deferred tax assets for which it is more likely than not that all or a portion of the deferred tax assets will not be realized.
The Company files U.S. federal and state and foreign income tax returns in jurisdictions with varying statutes of limitations. All tax returns from 2014 to 2019 may be subject to examination by the Internal Revenue Service, California and other states. Returns filed in foreign jurisdictions may be subject to examination for the years 2010 to 2019. As of March 31, 2021, the Company has not recorded any liability for unrecognized tax benefits related to uncertain tax positions.
Note 7. Stock-Based Compensation
Common Stock Equity Plans
In 2010, the Company adopted the 2010 Equity Incentive Plan and later amended it in 2014, 2017 and 2018 (the Amended 2010 Plan). The Amended 2010 Plan was terminated in August 2019 and remains in effect as to outstanding equity awards granted prior to the date of expiration. As of March 31, 2021, no new awards may be made under the Amended 2010 Plan, and equity awards for approximately 57,858 shares were outstanding.
In August 2019, the Company’s stockholders approved the 2019 Stock Incentive Plan (the 2019 Plan), and it replaced the Amended 2010 Plan. The 2019 Plan authorizes the board of directors or the compensation committee of the board of directors to grant a broad range of awards including stock options, stock appreciation rights, restricted stock, performance-based awards, and restricted stock units. Under the 2019 Plan, 182,500 shares have been reserved for issuance. The 2019 Plan provides for annual option grants or other awards to the Company’s non-employee directors to acquire up to 2,000 shares and for a one-time grant of an option or other award to a non-employee director to acquire up to 6,000 shares upon his or her initial appointment or election to the board of directors.
Under the 2019 Plan, the term of all incentive stock options granted to a person who, at the time of grant, owns stock representing more than 10% of the voting power of all classes of the Company’s stock may not exceed five years. The exercise price of stock options granted under the 2019 Plan must be at least equal to the fair market value of the shares on the date of grant. Generally, awards under the 2019 Plan will vest over a three to four-year period, and options will have a term of 10 years from the date of grant. In addition, the 2019 Plan provides for automatic acceleration of vesting for options granted to non-employee directors upon a change of control of the Company.
The Amended 2010 Plan and the 2019 Plan are referred to collectively as the “Plans.”
The expense relating to stock options is recognized on a straight-line basis over the requisite service period, usually the vesting period, based on the grant-date fair value. The unamortized compensation cost, as of March 31, 2021, was $0.1 million related to stock options and is expected to be recognized as expense over a weighted-average period of approximately 1.25 years. The expense related to restricted stock units (RSUs) is generally recognized over a three-year
12
vesting period and is based on the fair value of the underlying stock on the dates of grant. The unamortized compensation cost, as of March 31, 2021, was $0.2 million related to RSUs and is expected to be recognized as expense over a weighted-average period of approximately 0.5 years.
For the three months ended March 31, 2021 and 2020, there were no excess tax benefits associated with the exercise of stock options due to the Company’s historical loss positions.
Valuation Assumptions
There were no stock options granted during the three months ended March 31, 2021 and 2020.
Common Stock Options and Restricted Stock
The term of all incentive stock options granted to a person who, at the time of grant, owns stock representing more than 10% of the voting power of all classes of the Company’s stock may not exceed five years. The exercise price of stock options granted under the 2019 Plan must be at least equal to the fair market value of the shares on the date of grant. Generally, options granted under the 2019 Plan will vest over a three to four-year period and have a term of 10 years from the date of grant. In addition, the 2019 Plan provides for automatic acceleration of vesting for options granted to non-employee directors upon a change of control of the Company.
The following table summarizes the activity in the shares available for grant under the Plans during the three months ended March 31, 2021 (in thousands, except exercise price):
|
|
|
|
|
|
|
Options outstanding |
|
|||||
|
|
|
|
|
|
|
|
|
|
|
Weighted |
|
|
|
|
|
Shares |
|
|
|
|
|
|
Average |
|
||
|
|
|
Available |
|
|
Number of |
|
|
Exercise |
|
|||
|
|
|
for Grant |
|
|
Shares |
|
|
Prices |
|
|||
|
Balance as of January 1, 2021 |
|
|
81 |
|
|
|
159 |
|
|
$ |
10.82 |
|
|
RSUs granted |
|
|
(10 |
) |
|
|
— |
|
|
|
— |
|
|
Balance as of March 31, 2021 |
|
|
71 |
|
|
|
159 |
|
|
$ |
10.82 |
|
A summary of RSU activity under the Plans is presented below (in thousands, except for fair value):
|
|
|
|
|
|
|
Weighted |
|
|
|
|
|
|
|
|
|
Average |
|
|
|
|
|
Number of |
|
|
Grant-Date |
|
||
|
|
|
Shares |
|
|
Fair Value |
|
||
|
Non-vested shares as of January 1, 2021 |
|
|
65 |
|
|
$ |
3.48 |
|
|
Granted |
|
|
10 |
|
|
$ |
3.25 |
|
|
Vested |
|
|
(17 |
) |
|
$ |
3.78 |
|
|
Non-vested shares as of March 31, 2021 |
|
|
58 |
|
|
$ |
3.35 |
|
|
|
|
|
|
|
|
|
|
|
The fair value of the RSU granted during the three months ended March 31, 2021 was $32,500.
The total intrinsic value of the RSUs outstanding as of March 31, 2021 was $0.2 million.
13
The following table summarizes significant ranges of outstanding and exercisable options as of March 31, 2021 (in thousands, except contractual life and exercise price):
|
|
|
Options Outstanding |
|
|
Options Exercisable |
|
||||||||||||||||||
|
|
|
|
|
|
|
Weighted |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Average |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Remaining |
|
|
Weighted |
|
|
|
|
|
|
Weighted |
|
|
|
|
|
|||
|
|
|
|
|
|
|
Contractual |
|
|
Average |
|
|
|
|
|
|
Average |
|
|
Aggregate |
|
||||
|
|
|
Number |
|
|
Life |
|
|
Exercise |
|
|
Number |
|
|
Exercise |
|
|
Intrinsic |
|
||||||
|
Range of Exercise Price |
|
Outstanding |
|
|
(in Years) |
|
|
Price |
|
|
Exercisable |
|
|
Price |
|
|
value |
|
||||||
|
$1.57 - $14.99 |
|
|
143 |
|
|
|
8.01 |
|
|
$ |
2.62 |
|
|
|
79 |
|
|
$ |
2.88 |
|
|
$ |
185 |
|
|
$15.00 - $25.59 |
|
|
8 |
|
|
|
2.49 |
|
|
$ |
15.00 |
|
|
|
8 |
|
|
$ |
15.00 |
|
|
$ |
— |
|
|
$25.60 - $143.99 |
|
|
2 |
|
|
|
3.11 |
|
|
$ |
41.81 |
|
|
|
2 |
|
|
$ |
41.81 |
|
|
$ |
— |
|
|
$144.00 - $409.99 |
|
|
5 |
|
|
|
5.40 |
|
|
$ |
144.00 |
|
|
|
5 |
|
|
$ |
144.00 |
|
|
$ |
— |
|
|
$410.00 - $924.00 |
|
|
1 |
|
|
|
3.94 |
|
|
$ |
430.64 |
|
|
|
1 |
|
|
$ |
430.64 |
|
|
$ |
— |
|
|
$1.57 - $924.00 |
|
|
159 |
|
|
|
8.04 |
|
|
$ |
10.82 |
|
|
|
95 |
|
|
$ |
16.55 |
|
|
$ |
185 |
|
There were no stock options exercised during the three months ended March 31, 2021 or 2020.
Note 8: Stockholders’ Equity
In February 2021, the Company completed a registered direct offering of securities under an effective registration statement filed with the SEC pursuant to the Securities Act of 1933, as amended. In the offering, the Company sold 1,487,601 shares of common stock at a price of $5.00 per share to institutional investors. Net proceeds of the offering, after placement agent and other fees and expenses paid by the Company, were approximately $6.8 million.
During the three months ended March 31, 2021, the Company received a total of $2,478,461 of proceeds from the exercise of 1,032,692 warrants to purchase shares of common stock at a price of $2.40 per share.
Note 9. Notes Payable
Convertible Notes
In March 2016, the Company entered into a 10% Senior Secured Convertible Note Purchase Agreement (the Purchase Agreement) with the purchasers of $8,000,000 principal amount of 10% Senior Secured Convertible Notes due August 15, 2018 (the Notes), at par, in a private placement transaction effected pursuant to an exemption from the registration requirements under the Securities Act of 1933, as amended. Pursuant to amendments to the Notes and related documents in February and October 2018, the interest rate was reduced to 8%, the maturity date of the Notes was extended to August 15, 2023, and the optional conversion price was reduced from $170.00 of Note principal per share of common stock to $11.434 of Note principal per share of common stock.
In accordance with the October 2018 amendment to the Notes, the Company used $7.4 million of the proceeds from a public offering of securities effected in October 2018 to repay a portion of the Notes. Semi-annual interest payments have been made in each of February 2019, August 2019, February 2020 and August 2020 for approximately $78,000, $109,000, $112,000 and $122,000, respectively, in-kind with the issue of additional notes (Interest Notes) to the Purchasers. The Interest Notes have terms identical to the Notes.
The Company issued 42,672 shares of its common stock valued at $139,964 to the Note holder in settlement of the accrued interest for the six month period ended February 15, 2021. The Company recorded a loss of $16,898 on this payment, which was recorded in other income in the condensed consolidated statements of operation.
In January and February 2021, a holder of warrants, who was also the holder of the Notes, exercised warrants to purchase 613,791 shares of the Company’s common stock at an exercise price of $2.40 per share for total proceeds of $1,473,098. The proceeds from the exercise of these warrants were used to repay a portion of the principal amount of the Notes.
In March 2021, the Company made a repayment of $1,554,173 in settlement of the outstanding principal amount of the Notes, and the Note holder’s security interest was terminated. The Company recorded a gain of $64,757 on the Note settlement, and the gain was recorded in other income in the condensed consolidated statements of operations.
14
PPP Note
On May 7, 2020, the Company entered into a Promissory Note with Wells Fargo Bank, N.A. (the Lender) in an aggregate principal amount of $579,330 (the PPP Note), pursuant to the Paycheck Protection Program (the PPP) under the CARES Act.
The term of the PPP Note is two years. Interest will accrue on the outstanding principal balance of the PPP Note at a fixed rate of 1.0%, which shall be deferred for the first ten months of the term of the PPP Note. Monthly payments will be due and payable beginning in March 2021 and continue each month thereafter until maturity of the PPP Note. The Company may prepay principal of the PPP Note at any time in any amount without penalty. The Agreement contains customary events of default relating to, among other things, payment defaults, breach of representations and warranties or provisions of the PPP Note. The occurrence of an event of default may result in the repayment of all amounts outstanding, collection of all amounts owing from the Company, and/or filing suit and obtaining judgment against the Company.
The Company applied to the Lender for forgiveness of the PPP Note, under the terms of the PPP. No assurance is provided that the Company will obtain forgiveness of the PPP Note in whole or in part, but the Company believes it has used the proceeds in accordance with the PPP. If the PPP Note is not forgiven, principal payments will be due: $217,250 in 2021 and $362,080 in 2022.
Note 10. Leases
The Company has one lease, which is the lease for its corporate facility that expires in July 2022, that it accounts for under Accounting Standards Update 2016-02. The right-of-use asset and corresponding liability for the facility lease have been measured at the present value of the future minimum lease payments. The discount rate used to measure the lease asset and liability represents the interest rate on the Notes (8%). Lease expense is recognized on a straight-line basis over the lease term, and operating lease expense was approximately $53,000 for the three months ended March 31, 2021. The Company does not have an option to extend the lease term beyond the current extension.
Future minimum payments under the facility operating lease at March 31, 2021 are as follows (in thousands):
|
|
|
Operating |
|
|
|
Year ending December 31, |
|
lease |
|
|
|
2021 |
|
$ |
155 |
|
|
2022 |
|
|
112 |
|
|
Total future lease payments |
|
|
267 |
|
|
Less: imputed interest |
|
|
(9 |
) |
|
Present value of lease liabilities |
|
$ |
258 |
|
|
|
|
|
|
|
Supplemental cash flow information related to the operating lease was as follows (in thousands):
|
|
|
|
|
|
Three Months Ended |
|
|||||
|
|
|
|
|
|
March 31, |
|
|||||
|
|
|
|
|
|
2021 |
|
|
2020 |
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash paid for amounts included in the measurement of lease liabilities: |
|
|
|
|
|
|
|
||||
|
|
Operating cash flows for lease |
|
|
|
$ |
51 |
|
|
$ |
56 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
15
ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
This Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the accompanying condensed consolidated financial statements and notes included in this report. This Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which include, without limitation, statements about the market for our technology, our strategy, competition, expected financial performance and capital raising efforts, the impacts of COVID-19 on our business, and other aspects of our business identified in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission on March 18, 2021 and in other reports that we file from time to time with the Securities and Exchange Commission. Any statements about our business, financial results, financial condition and operations contained in this Form 10-Q that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “expects,” “intends,” “plans,” “projects” or similar expressions are intended to identify forward-looking statements. Our actual results could differ materially from those expressed or implied by these forward-looking statements as a result of various factors, including the risk factors described under Item 1A of our annual report on Form 10-K for the year ended December 31, 2020 and the risk factors described below under Item 1A of this Form 10-Q. We undertake no obligation to update publicly any forward-looking statements for any reason, except as required by law, even as new information becomes available or events occur in the future.
Company Overview
Our strategy and primary business objective is to be a profitable intellectual property-rich fabless semiconductor company offering integrated circuits, or ICs, and related software, firmware and intellectual property, or IP, that deliver unparalleled memory bandwidth and access rate performance for high-performance data processing in cloud networking, communications, security appliances, video, test and monitoring, and data center systems. Our solutions deliver time-to-market, performance, power, area and economic benefits for system original equipment manufacturers, or OEMs. Our primary product line is marketed under the Accelerator Engine name and comprises our Bandwidth Engine and Programmable HyperSpeed Engine IC products, which integrate our proprietary, 1T-SRAM high-density embedded memory and a highly-efficient serial interface protocol resulting in a monolithic memory IC solution optimized for memory bandwidth and transaction access performance. Our second-generation Bandwidth Engine, or Bandwidth Engine 2, products are expected to be our primary revenue source through at least 2021, and we expect these products to continue to generate significant revenue thereafter. As we are not developing new IC products, from a product development perspective, we continue to leverage our current technologies and core competencies to expand our product offerings without incurring significant additional R&D expenses. We are developing our Virtual Accelerator Engine, or VAE, product line consisting of software, firmware and IP available for license. This product line will include multiple function accelerator platform products, which target specific application functions and will use a common software interface to allow performance scalability over multiple hardware environments. These function accelerator platform products are hardware agnostic and operate with or without one of our Accelerator Engine ICs. This software-defined, hardware-accelerated platform architecture utilizes an internally developed graphical memory engine architecture to provide flexible data classification and analysis capability. We believe the technology will generate new opportunities that require less up-front architectural changes by system designers and provide a scalable performance roadmap of options using our Accelerator Engine ICs. Despite our limited new IC product development efforts, we believe our current hardware and software/firmware product portfolio positions us for future growth and profitability.
We incurred net losses of approximately $1.4 million for the three months ended March 31, 2021 and $3.8 million and $2.6 million for the years ended December 31, 2020 and 2019, respectively, and had an accumulated deficit of approximately $244.0 million as of March 31, 2021. These and prior year losses have resulted in significant negative cash flows for almost a decade and have necessitated that we raise substantial amounts of additional capital during this period. To date, we have primarily financed our operations through multiple offerings of common stock to investors and affiliates, as well as asset sale transactions and one offering of convertible notes.
We may continue to incur operating losses and will need to increase revenues substantially beyond levels that we have attained in the past in order to generate sustainable operating profit and sufficient cash flows to continue doing business without raising additional capital from time to time.
16
COVID-19
The global outbreak of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency by the U.S. government in March 2020. This has negatively affected the U.S. and global economy, disrupted global supply chains, significantly restricted travel and transportation, resulted in mandated closures and orders to “shelter-in-place” and created significant disruption of the financial markets. The full extent of the COVID-19 impact on our operational and financial performance will depend on future developments, including the duration and spread of the pandemic and related actions taken by the U.S. and foreign government agencies to prevent disease spread, all of which are uncertain, out of our control, and cannot be predicted.
In March 2020, Santa Clara County in California, where we are based, issued a ”shelter-in-place” order (the Order) that was effective through the first quarter of 2021. We have been complying with the Order and have minimized business activities at our San Jose headquarters facility (our only facility) since March 2020. We have implemented a teleworking policy for our employees and contractors to reduce on-site activity at our facility. The Order impacted our ability to produce and ship our IC products in the second half of March 2020, as certain of our vendors in the San Francisco Bay Area closed in accordance with the Order. In April 2020, we resumed shipments of our IC products, as we and our vendors are supporting shipment of components for critical infrastructure, as defined by the federal government; however, our employees are still generally restricted from visiting our customer and vendor sites, and we are unable to conduct certain product testing and development activities.
We remain diligent in continuing to identify and manage risks to our business given the changing uncertainties related to COVID-19. The ultimate impact of the Covid-19 pandemic on our business and results of operations is uncertain and difficult to predict, and we are closely monitoring impacts, especially to customer programs and our supply chain. We expect that the impacts of the COVID-19 pandemic will continue to have a negative impact on our revenues for the remainder of 2021, although we are not in a position to quantify such impacts. In addition, we have and continue to experience longer lead times for certain components used to manufacture our IC products. While we believe that our operations personnel are currently in a position to meet expected customer demand levels in the coming quarters, we recognize that unpredictable events could create difficulties in the months ahead. We may not be able to address these difficulties in a timely manner, which could negatively impact our business, results of operations, financial condition and cash flows.
The continued spread of COVID-19 has also led to disruption and volatility in the global capital markets. During the quarter ended March 31, 2021, we were able to raise additional capital and make full repayment of our convertible notes payable (see discussion below under Liquidity and in Notes 8 and 9 to the condensed consolidated financial statements included in Part I, Item I of this Form 10-Q), however, if we need to raise additional capital to support operations in the future, we may be unable to access the capital markets and additional capital may only be available to us on terms that could be significantly detrimental to our existing stockholders and to our business.
For additional information on risks that could impact our future results, please refer to “Risk Factors” in Part II, Item 1A. of this quarterly report on Form 10-Q.
Sources of Revenue
Product. Product revenue is generally recognized at the time of shipment to our customers. An estimated allowance may be recorded, at the time of shipment, for future returns and other charges against revenue consistent with the terms of sale.
Royalty and other. Our licensing contracts typically provide for royalties based on the licensee’s use of our memory technology in their currently shipping commercial products. We estimate royalty revenue in the period in which the licensee uses the licensed technology. Payments are received in the following period.
17
Critical Accounting Policies and Estimates
The discussion and analysis of our financial condition and results of operations are based upon our condensed consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of these condensed consolidated financial statements requires us to make certain estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. On an ongoing basis we make these estimates based on our historical experience and on assumptions that we consider reasonable under the circumstances. Actual results may differ from these estimates and reported results could differ under different assumptions or conditions. Our significant accounting policies and estimates are disclosed in Note 1 of the “Notes to Consolidated Financial Statements” in our annual report on Form 10-K for the year ended December 31, 2020. As of March 31, 2021, there have been no material changes to our significant accounting policies and estimates.
Results of Operations
Net Revenue
|
|
|
March 31, |
|
|
Change |
|
||||||||||
|
|
|
2021 |
|
|
2020 |
|
|
2020 to 2021 |
|
|||||||
|
|
|
(dollar amounts in thousands) |
|
|||||||||||||
|
Product -three months ended |
|
$ |
1,178 |
|
|
$ |
1,068 |
|
|
$ |
110 |
|
|
|
10 |
% |
|
Percentage of total net revenue |
|
|
88 |
% |
|
|
85 |
% |
|
|
|
|
|
|
|
|
Product revenue increased for the three months ended March 31, 2021 compared with the same period of 2020 primarily due to higher sales of our Bandwidth Engine 2 products, partially offset by decreases in our LineSpeed product sales.
|
|
|
March 31, |
|
|
Change |
|
||||||||||
|
|
|
2021 |
|
|
2020 |
|
|
2020 to 2021 |
|
|||||||
|
|
|
(dollar amounts in thousands) |
|
|||||||||||||
|
Royalty and other -three months ended |
|
$ |
160 |
|
|
$ |
192 |
|
|
$ |
(32 |
) |
|
|
(17 |
)% |
|
Percentage of total net revenue |
|
|
12 |
% |
|
|
15 |
% |
|
|
|
|
|
|
|
|
Royalty and other includes license, royalty and related revenues generated from licensing agreements. The decrease in royalty and other revenue for the three months ended March 31, 2021 compared with the same period of 2020 was primarily due to a decrease in royalty revenue for one licensee.
Cost of Net Revenue and Gross Profit
|
|
|
March 31, |
|
|
Change |
|
||||||||||
|
|
|
2021 |
|
|
2020 |
|
|
2020 to 2021 |
|
|||||||
|
|
|
(dollar amounts in thousands) |
|
|||||||||||||
|
Cost of net revenue -three months ended |
|
$ |
495 |
|
|
$ |
530 |
|
|
$ |
(35 |
) |
|
|
(7 |
)% |
|
Percentage of total net revenue |
|
|
37 |
% |
|
|
42 |
% |
|
|
|
|
|
|
|
|
|
|
|
March 31, |
|
|
Change |
|
||||||||||
|
|
|
2021 |
|
|
2020 |
|
|
2020 to 2021 |
|
|||||||
|
|
|
(dollar amounts in thousands) |
|
|||||||||||||
|
Gross profit -three months ended |
|
$ |
843 |
|
|
$ |
730 |
|
|
$ |
113 |
|
|
|
15 |
% |
|
Percentage of total net revenue |
|
|
63 |
% |
|
|
58 |
% |
|
|
|
|
|
|
|
|
Cost of net revenue is primarily comprised of direct and indirect costs related to the sale of our IC products.
Cost of net revenue decreased for the three months ended March 31, 2021 when compared with the same period in 2020, primarily due to decreased shipment volumes of our LineSpeed product which was only partially offset by the increase of our Bandwidth Engine products that have lower production costs.
Gross profit increased for the three months ended March 31, 2021 compared with the same period of 2020 due to the increase in gross profit attributable to the increases in product revenues. As a percentage of net revenue, gross profit
18
increased due to higher gross margins on our product sales and higher royalty and other revenue, which generally has no associated cost.
Research and Development
|
|
|
March 31, |
|
|
Change |
|
||||||||||
|
|
|
2021 |
|
|
2020 |
|
|
2020 to 2021 |
|
|||||||
|
|
|
(dollar amounts in thousands) |
|
|||||||||||||
|
Research and development -three months ended |
|
$ |
1,159 |
|
|
$ |
961 |
|
|
$ |
198 |
|
|
|
21 |
% |
|
Percentage of total net revenue |
|
|
87 |
% |
|
|
76 |
% |
|
|
|
|
|
|
|
|
Our research and development expenses include costs related to the development of our IC and VAE IP products. We expense research and development costs as they are incurred.
The increase for the three months ended March 31, 2021 compared with the same period of 2020 was primarily due to increases in personnel costs due to new hires and increases in consulting costs for development of our VAE products. We expect that total research and development expenses will increase in 2021 compared with 2020 as we incur increased development costs for our VAE products.
Selling, General and Administrative
|
|
|
March 31, |
|
|
Change |
|
||||||||||
|
|
|
2021 |
|
|
2020 |
|
|
2020 to 2021 |
|
|||||||
|
|
|
(dollar amounts in thousands) |
|
|||||||||||||
|
SG&A -three months ended |
|
$ |
1,071 |
|
|
$ |
1,135 |
|
|
$ |
(64 |
) |
|
|
(6 |
)% |
|
Percentage of total net revenue |
|
|
80 |
% |
|
|
90 |
% |
|
|
|
|
|
|
|
|
Selling, general and administrative, or SG&A, expenses consist primarily of personnel and related overhead costs for sales, marketing, finance, human resources and general management.
The decrease for the three months ended March 31, 2021 compared with the same period of 2020 was primarily due to decreases in professional services and facilities and travel costs, partially offset by increased legal and personnel costs. We expect total SG&A expenses to remain relatively consistent for the remainder of 2021.
Interest expense
|
|
|
March 31, |
|
|
Change |
|
||||||||||
|
|
|
2021 |
|
|
2020 |
|
|
2020 to 2021 |
|
|||||||
|
|
|
(dollar amounts in thousands) |
|
|||||||||||||
|
Interest expense - three months ended |
|
$ |
30 |
|
|
$ |
54 |
|
|
$ |
(24 |
) |
|
|
(44 |
)% |
|
Percentage of total net revenue |
|
|
2 |
% |
|
|
4 |
% |
|
|
|
|
|
|
|
|
Interest expense consisted of interest expense on our senior secured convertible notes (the Notes). As of March 31, 2021, we had repaid the full remaining principal amount of the Notes and accrued interest. We do not expect to incur interest expense during the remainder of 2021. See Note 9 to the condensed consolidated financial statements for additional disclosure.
Liquidity and Capital Resources; Changes in Financial Condition
Cash Flows
As of March 31, 2021, we had cash, cash equivalents and short-term investments of $11.1 million and working capital of $10.9 million. We believe that cash generated from our liquidity sources will be sufficient to meet both our short-term and long-term working capital and capital expenditure needs for the foreseeable future.
19
Net cash used in operating activities was $1.0 million for the first three months of 2021, which primarily resulted from our net loss of $1.4 million, which was partially offset by $0.3 million in net changes in assets and liabilities and non-cash charges of $0.1 million. The changes in assets and liabilities primarily related to the timing of accounts receivable collections, purchases of inventory and other vendor payables and prepayments.
Net cash used in operating activities was $0.7 million for the first three months of 2020, which primarily resulted from our net loss of $1.4 million, which was partially offset by $0.5 million in net changes in assets and liabilities and non-cash charges of $0.1 million of stock-based compensation, depreciation and amortization expenses and $0.1 million of accrued interest. The changes in assets and liabilities primarily related to the timing of customer collections, and inventory and other vendor payables and prepayments.
Net cash used in investing activities of $1.6 million for the three months ended March 31, 2021 represented purchases of short-term investments. Net cash provided by investing activities for the three months ended March 31, 2020 was mainly due to the proceeds from the maturities of short-term investments of $0.3 million.
Net cash provided by financing activities of $6.3 million for the three months ended March 31, 2021 primarily consisted of $6.8 million in net proceeds received from the registered direct offering of our common stock completed in February 2021 and $2.5 million of proceeds from the exercise of warrants to purchase shares of common stock at a price of $2.40 per share. We used approximately $3 million of these proceeds to repay in full the outstanding balance of our senior secured convertible notes. There were minimal cash flows used in financing activities during the three months ended March 31, 2020.
Our future liquidity and capital requirements are expected to vary from quarter-to-quarter, depending on numerous factors, including:
|
|
• |
level of revenue; |
|
|
• |
cost, timing and success of technology development efforts, especially for our VAE products; |
|
|
• |
inventory levels, timing of product shipments and length of billing and collection cycles; |
|
|
• |
variations in manufacturing yields, material lead time and costs and other manufacturing risks; |
|
|
• |
profitability of our business; |
|
|
• |
costs of acquiring other businesses and integrating the acquired operations; and |
|
|
• |
whether the PPP Note is substantially forgiven. |
Working Capital
Our primary need for liquidity is to fund working capital requirements of our businesses, capital expenditures and for general corporate purposes. We expect our cash expenditures to exceed receipts in 2021, as our revenues will not be sufficient to offset our working capital requirements. During the three months ended March 31, 2021, we received proceeds of $2.5 million from the exercise of common stock warrants, and we used $1.5 million of these proceeds to repay a portion of the principal balance of our senior secured convertible notes. In February 2021, we completed a registered direct offering of securities that generated net proceeds of approximately $6.8 million. In May 2020, we entered into a Promissory Note with Wells Fargo Bank, N.A. in an aggregate principal amount of approximately $0.6 million (the PPP Note), pursuant to the Paycheck Protection Program (the PPP) under the CARES Act. In March 2021 we applied for forgiveness of the PPP Note under the terms of the PPP. No assurance is provided that we will obtain forgiveness of the PPP Note in whole or in part, but we believe we have used the proceeds in accordance with the PPP.
In the event that additional financing is required through sales of our equity securities, our stockholders would suffer dilution of their equity ownership, and we may be required to accept other terms that could be significantly detrimental to our existing stockholders and to our business. If we engage in debt financing, we may be required to accept terms that restrict our ability to incur additional indebtedness, prohibit us from paying dividends, repurchasing our stock or making investments, and force us to maintain specified liquidity or other ratios, any of which could be significantly detrimental
20
to our business, operating results and financial condition. If we need additional capital and cannot raise it on acceptable terms, we may not be able to, among other things:
|
|
• |
develop or enhance our products; |
|
|
• |
expand our product development and sales and marketing organizations; |
|
|
• |
acquire complementary technologies, products or businesses; |
|
|
• |
expand operations; |
|
|
• |
hire, train and retain employees; or |
|
|
• |
respond to competitive pressures or unanticipated working capital requirements. |
Our failure to do any of these things could seriously harm our ability to execute our business strategy and may force us to curtail our existing operations or research and development plans.
Off-Balance Sheet Arrangements
We do not maintain any off-balance sheet arrangements or obligations that are reasonably likely to have a material current or future effect on our financial condition, results of operations, liquidity or capital resources.
ITEM 4. Controls and Procedures
Disclosure Controls and Procedures. Our management is responsible for establishing and maintaining adequate internal control over our financial reporting. Because of inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934. Based on this evaluation, our management concluded that, as of March 31, 2021, our disclosure controls and procedures were effective.
Changes in Internal Control over Financial Reporting. During the three months ended March 31, 2021, there was no change in our internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
The discussion of legal matters in Note 4 of the Notes to Condensed Consolidated Financial Statements included in Part I, Item 1 of this report under the heading “Legal Matters” is incorporated by reference in response to this Part II, Item 1.
We face many significant risks in our business, some of which are unknown to us and not presently foreseen. These risks could have a material adverse impact on our business, financial condition and results of operations in the future. Except as set forth below, there have been no material changes with respect to the risk factors disclosed under Item 1A of our annual report on Form 10-K for the year ended December 31, 2020, which we filed with the SEC on March 18, 2021.
21
The full effects of COVID-19 and other potential future public health crises, epidemics, pandemics or similar events are uncertain and could have a material and adverse effect on our business, financial condition, operating results and cash flows.
The global outbreak of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency by the U.S. government in March 2020. This has negatively affected the world economy, disrupted global supply chains, significantly restricted travel and transportation, resulted in mandated closures and orders to “shelter-in-place” and created significant disruption of the financial markets. The extent of the impact on our operational and financial performance will depend on future developments, including the duration and spread of the pandemic and related actions taken by U.S. and foreign government agencies to prevent disease spread, all of which are uncertain, out of our control and cannot be predicted.
In accordance with applicable U.S. governmental ordinances generally exempting essential businesses and/or critical infrastructure workforces from mandated closures and orders to “shelter-in-place,” we are operating in support of essential products and services, subject to limitations and requirements in applicable state and county orders. We have been complying with county and state orders and have implemented a work-from-home policy for our employees and contractors and significantly minimized the number of employees who visit our office. However, a facility closure, work slowdowns or temporary stoppage at one of our production vendors could occur, which could have a longer-term impact and could delay our deliveries to customers and ability to conduct business. For example, the “shelter-in-place” orders impacted our ability to produce and ship our IC products in the second half of March, as certain of our vendors in the San Francisco Bay Area closed in accordance with governmental orders.
If significant portions of our workforce are unable to work effectively, including because of illness, quarantines, absenteeism, government actions, facility closures, travel restrictions or other restrictions in connection with the COVID-19 pandemic, our operations will be negatively impacted. We may be unable to market and sell our products, and our costs may increase as a result of the COVID-19 outbreak. The impacts could worsen if there is an extended duration of any COVID-19 outbreak or a resurgence of COVID-19 infection in affected regions after they have begun to experience improvement.
We rely on other companies to provide raw materials and to perform manufacturing and testing of our products. An extended period of global supply chain disruption, including extended lead times to purchase materials or procure testing services caused by the response to COVID-19 could impact our ability to ship our products. For example, we have already experienced longer lead times for certain components used to manufacture our IC products. If we are not able to implement alternatives or other mitigations, product deliveries would be adversely impacted and negatively impact our business, financial condition, operating results and cash flows.
As a result of COVID-19, we could see delays in new customer product programs and reduced customer demand for our products, which would adversely affect our revenues, financial performance and cash flows, and could result in asset impairments. Delays in transaction processing, including payment processing, by our customers, many of whom are teleworking, could also affect our revenues and cash flows, and current limitations on travel to customers could impact orders and business prospects. Limitations on government operations can also impact regulatory approvals that may be necessary for us to operate our business.
The continued spread of COVID-19 has also led to disruption and volatility in the global capital markets. We were recently able to raise additional capital, however, if we need to raise additional capital to support operations in the future, we may be unable to access the capital markets and additional capital may only be available to us on terms that could be significantly detrimental to our existing stockholders and to our business.
ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds
|
|
(a) |
Unregistered sales of equity securities: |
On February 1, 2021, the Company issued 42,672 shares of its common stock valued at $139,964 to the holder of the Senior Secured Convertible Notes due August 15, 2023 in settlement of the accrued interest for the six month period ended February 15, 2021. Such shares were issued in a private placement transaction that was exempt from the registration requirements under the Securities Act pursuant to Section 4(a)(2) of the Securities Act.
22
|
(a) |
Exhibits |
|
|
|
|
|
|
|
10.22(1) |
Form of Securities Purchase Agreement dated February 17, 2021 |
|
|
10.23* |
First Amendment to Executive Severance and Change-In-Control Policy dated April 28, 2021 |
|
|
31.1* |
|
|
|
31.2* |
|
|
|
32.1** |
|
|
|
101* |
The following financial information from MoSys, Inc.’s quarterly report on Form 10-Q for the period ended March 31, 2021, filed with the SEC on May 13, 2021, formatted in Extensible Business Reporting Language (XBRL): (i) the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) for the three months ended March 31, 2021 and 2020, (ii) the Condensed Consolidated Balance Sheets as of March 31, 2021 and December 31, 2020, (iii) the Condensed Consolidated Statements of Changes in Stockholders’ Equity for the three months ended March 31, 2021 and 2020, (iv) the Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2021 and 2020, and (v) Notes to Condensed Consolidated Financial Statements. |
|
|
|
|
|
|
(1) |
Incorporated by reference to Exhibit 10.1 to Form 8-K filed by the Company on February 17, 2021 (Commission File No. 000-32929 |
|
|
|
|
*Filed herewith.
**Furnished herewith.
23
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
|
|
Dated: May 13, 2021 |
|
MOSYS, INC. |
|
|
|
|
|
|
By: |
/s/ Daniel Lewis |
|
|
|
Daniel Lewis |
|
|
|
President and Chief Executive Officer (Principal Executive Officer) |
|
|
|
|
|
|
By: |
/s/ James W. Sullivan |
|
|
|
James W. Sullivan |
|
|
|
Vice President of Finance and Chief Financial Officer |
|
|
|
(Principal Financial and Accounting Officer) |
24
Exhibit 10.23
MOSYS, INC.
FIRST AMENDMENT TO
EXECUTIVE CHANGE-IN-CONTROL AND SEVERANCE POLICY
This First Amendment (this “Amendment”) to the Executive Change-in-Control and Severance Policy (the “Policy”) of MoSys, Inc., a Delaware corporation (the “Company”), is entered into on April 28, 2021 but made effective as of April 27, 2019 (the “Effective Date”). Capitalized terms used herein and not otherwise defined shall have the meanings ascribed to such terms in the Policy.
WHEREAS, the Company adopted the Policy effective as of April 27, 2016 (the “Adoption Date”);
WHEREAS, from the Adoption Date through the date hereof, the Company has continuously maintained and administered the Policy for the benefit of Executives, notwithstanding the expiration of the Policy in accordance with its terms on April 27, 2019;
WHEREAS, the Board of Directors of the Company (the “Board”) has the authority to amend the Policy pursuant to and in accordance with Section 9 of the Policy; and
WHEREAS, the Board desires to retroactively amend the Policy as set forth herein.
NOW, THEREFORE, the Policy is hereby amended as follows, effective as of the Effective Date:
|
|
1. |
Amendment to the Policy. Section 9 of the Policy is hereby amended and restated in its entirety to read as follows: |
“9. DURATION; AMENDMENT OR TERMINATION
9.1. Duration. This Policy will be effective from the Effective Date and will continue in effect until it is terminated as provided in Section 9.2.
9.2. Amendments; Termination. The Board will have the right to amend or terminate this Policy at any time in its sole discretion; provided, however that any amendment or termination reasonably determined to have an adverse effect on any then-eligible Executives or within twenty-four (24) months after a Change-in-Control will not be effective without the express written consent of such adversely affected Executives.”
|
|
2 |
This Amendment is hereby incorporated into and made a part of the Policy as of the Effective Date. |
|
|
3 |
Except as expressly amended by this Amendment, all terms and conditions of the Policy shall remain in full force and effect. |
[Signature Page Follows]
13065317.3
The undersigned hereby certifies that the foregoing Amendment to the Policy was duly adopted by the Board on April 28, 2021.
/s/ Daniel Lewis
Daniel Lewis, Chief Executive Officer
Exhibit 31.1
CERTIFICATION PURSUANT TO
RULE 13a-14 THE SECURITIES EXCHANGE ACT OF 1934
I, Daniel Lewis, certify that:
|
|
1. |
I have reviewed this quarterly report on Form 10-Q of MoSys, Inc. for the period ended March 31, 2021; |
|
|
2. |
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
|
|
3. |
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
|
|
4. |
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
|
|
(a) |
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
|
|
(b) |
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
|
|
(c) |
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
|
|
(d) |
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
|
|
5. |
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
|
|
(a) |
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
|
|
(b) |
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
|
|
|
|
Date: May 13, 2021 |
|
|
|
|
|
/s/ Daniel Lewis |
|
|
Daniel Lewis |
|
|
President and Chief Executive Officer (Principal Executive Officer) |
|
Exhibit 31.2
CERTIFICATION PURSUANT TO
RULE 13a-14 THE SECURITIES EXCHANGE ACT OF 1934
I, James W. Sullivan, certify that:
|
|
1. |
I have reviewed this quarterly report on Form 10-Q of MoSys, Inc. for the period ended March 31, 2021; |
|
|
2. |
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
|
|
3. |
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
|
|
4. |
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
|
|
(a) |
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
|
|
(b) |
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
|
|
(c) |
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
|
|
(d) |
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
|
|
5. |
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
|
|
(a) |
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
|
|
(b) |
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
|
|
|
|
Date: May 13, 2021 |
|
|
|
|
|
/s/ James W. Sullivan |
|
|
James W. Sullivan |
|
|
Vice President of Finance and Chief Financial Officer (Principal Financial and Accounting Officer) |
|
Exhibit 32.1
CERTIFICATION OF CEO AND CFO FURNISHED PURSUANT TO
18 U.S.C. § 1350,
AS ADOPTED PURSUANT TO
§ 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the quarterly report on Form 10-Q of MoSys, Inc. (the “Company”) for the quarterly period ended March 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of Daniel Lewis, Chief Executive Officer of the Company, and James W. Sullivan, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, to the best of his knowledge, that:
(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
|
/s/ Daniel Lewis |
|
|
Daniel Lewis |
|
|
President and Chief Executive Officer (Principal Executive Officer) |
|
|
May 13, 2021 |
|
|
|
|
|
/s/ James W. Sullivan |
|
|
James W. Sullivan |
|
|
Vice President of Finance and Chief Financial Officer (Principal Financial and Accounting Officer) |
|
|
May 13, 2021 |
This certification accompanies this Report pursuant to § 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, or otherwise required, be deemed filed by the Company for purposes of § 18 of the Securities Exchange Act of 1934, as amended.